Abstract

In Uganda, 12% of previously treated TB cases and 1.6% of new cases have MDR-TB and require specialized treatment and care. Adherence is crucial for improving MDR-TB treatment outcomes. There is paucity of information on the extent to which these patients adhere to treatment and what the drivers of non-adherence are. We conducted a cohort study using retrospectively collected routine program data for patients treated for MDR-TB between January 2012 - May 2016 at Mulago Hospital. We extracted anonymized data on non-adherence (missing 10% or more of DOT), socio-economic, demographic, and treatment characteristics of the patients. All participants were sensitive to MDR-TB drugs after second line Drug Susceptible Testing (DST) at entry into the study. Factors associated with non-adherence to MDR-TB treatment were determined using generalized linear models for the binomial family with log link and robust standard errors. We considered a p- value less than 0.05 as statistically significant. The records of 227 MDR- TB patients met the inclusion criteria, 39.4% of whom were female, 32.6% aged between 25 - 34 years, and 54.6% living with HIV/AIDS. About 11.9% of the patients were non-adherent. The main driver for non-adherence was history of previous DR-TB treatment; previously treated DR-TB patients were 3.46 (Adjusted prevalence ratio: 3.46, 95 % CI: 1.68 - 7.14) times more likely to be non-adherent. One in 10 MDR-TB patients treated at Mulago hospital is non-adherent to treatment. History of previous DRTB treatment was significantly associated with non-adherence in this study. MDR-TB program should strengthen adherence counselling, strengthen DST surveillance, and close monitoring for previously treated DR-TB patients.

Highlights

  • Multi Drug Resistant / Rifampicin Resistant TB (MDRTB/RR-TB) is one of the global public health prob-African Health SciencesAfrican Health Sciences, Vol 21 Issue 1, March, 2021(with an approximate duration of 18 to 24 months)

  • We present the prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment using secondary data from Mulago National Referral Hospitalthe largest MDR-TB treatment center in Uganda

  • 1 in 10 MDR-TB patients treated at the Mulago National Referral Hospital in Kampala, Uganda is non-adherent to treatment

Read more

Summary

Introduction

Multi Drug Resistant / Rifampicin Resistant TB (MDRTB/RR-TB) is one of the global public health prob-African Health SciencesAfrican Health Sciences, Vol 21 Issue 1, March, 2021(with an approximate duration of 18 to 24 months). Other adverse events due to MDRTB treatment include; renal failure and nerve damage[10] These adverse effects combined with the long treatment period and cost to the patients immensely affect patients’ adherence to treatment and treatment outcomes. Methods: We conducted a cohort study using retrospectively collected routine program data for patients treated for MDRTB between January 2012 – May 2016 at Mulago Hospital. Conclusion: One in 10 MDR-TB patients treated at Mulago hospital is non-adherent to treatment. MDR-TB program should strengthen adherence counselling, strengthen DST surveillance, and close monitoring for previously treated DR-TB patients. Prevalence and factors associated with nonadherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda.

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call